Wedbush Maintains Outperform on Artiva Biotherapeutics, Raises Price Target to $40

Wedbush analyst Martin Fan maintains Artiva Biotherapeutics (NASDAQ:ARTV) with a Outperform and raises the price target from $23 to $40.